Gene therapy for rheumatoid arthritis: Current status and future prospects

BioDrugs

Volumn 25, Issue 6, 2011, Pages 381-391

  Fabre, Sylvie ^a,b,c   Apparailly, Florence ^a,b,c  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Gene therapies; Rheumatoid arthritis

Indexed keywords

4SC AG; AIN 457; AMG 714; ANTIRHEUMATIC AGENT; APREMILAST; ATACICEPT; BAMINERCEPT; BELATACEPT; BELIMUMAB; CAM 3001; CANAKINUMAB; CDP 6038; CE 224535; DENOSUMAB; ETANERCEPT; ETARACIZUMAB; FOSTAMATINIB; ISIS 104838; MARAVIROC; MASITINIB; MAVRILIMUMAB; NATALIZUMAB; OFATUMUMAB; OLOKIZUMAB; PH 797804; RIMACALIB; SC 12267; SECUKINUMAB; SITIMAGENE CERADENOVEC; TALMAPIMOD; TASOCITINIB; TGAAC 94; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDOFLUDIMUS; VX 702;

ANTISENSE THERAPY; CELL ADHESION; CELL DIVISION; CELL INTERACTION; CYTOMEGALOVIRUS; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO GENE TRANSFER; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; HUMAN; IN VIVO GENE TRANSFER; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INTRACELLULAR SIGNALING; JOINT SWELLING; LOCAL THERAPY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TRANSGENE; VIRUS CAPSID;

ANIMALS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS;

EID: 80555127435     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11595490-000000000-00000     Document Type: Review

References (70)

1. Evans CH, Robbins PD, Ghivizzani SC, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996 Jun; 7 (10): 1261-80
2. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003 Sep-Oct; 80 (1-2): 148-58
3. Williams DA.RACreviews serious adverse event associated withAAVtherapy trial. Mol Ther 2007 Dec; 15 (12): 2053-4
4. Wilson JM. Gendicine: the first commercial gene therapy product. Hum Gene Ther 2005 Sep; 16 (9): 1014-5
5. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000 Apr; 288 (5466): 669-72
6. Wehling P, Reinecke J, Baltzer AW, et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther 2009 Feb; 20 (2): 97-101
7. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy for arthritis: what next? Arthritis Rheum 2006 Jun; 54 (6): 1714-29
8. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy of the rheumatic diseases: 1998 to 2008. Arthritis Res Ther 2009; 11 (1): 209
9. Sewell KL, Geary RS, Baker BF, et al. Phase I trial of ISIS 104838, a 20- methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002 Dec; 303 (3): 1334-43
10. Kennewell P. Technology evaluation: ISIS-104838, OraSense. Curr Opin Mol Ther 2003 Feb; 5 (1): 76-80
11. ISIS 104838, an inhibitor of tumor necrosis factor, for active rheumatoid arthritis [ClinicalTrials.gov identifier: NCT00048321]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinical trials.gov [Accessed 2011 Oct 4]
12. Mease PJ, Hobbs K, Chalmers A, et al. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis 2009 Aug; 68 (8): 1247-54
13. Mease PJ,Wei N, Fudman EJ, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Rheumatol 2010 Apr; 37 (4): 692-703
14. Evans CH, Robbins PD, Ghivizzani SC, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A 2005; 102: 8698-703
15. Lefèvre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009 Dec; 15 (12): 1414-20
16. Evans CH, Ghivizzani SC, Robbins PD. Getting arthritis gene therapy into the clinic. Nat Rev Rheumatol 2011 Apr; 7 (4): 244-9
17. Hacein-Bey-Abina S,Garrigue A,Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008 Sep; 118 (9): 3132-42
18. Ghivizzani SC, Lechman ER, Kang R, et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A 1998 Apr; 95 (8): 4613-8
19. Kim SH, Lechman ER, Kim S, et al. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigeninduced arthritis. Mol Ther 2002 Nov; 6 (5): 591-600
20. Lechman ER, Keravala A, Nash J, et al. The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Ther 2003 Nov; 10 (24): 2029-35
21. Agha-Mohammadi S, Lotze MT. Regulatable systems: applications in gene therapy and replicating viruses. J Clin Invest 2000 May; 105 (9): 1177-83
22. Apparailly F, Millet V, Noël D, et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 2002 Jul; 13 (10): 1179-88
23. Zhang HG, Hyde K, Page GP, et al. Novel tumor necrosis factor alpharegulated genes in rheumatoid arthritis. Arthritis Rheum 2004 Feb; 50 (2): 420-31
24. Gould DJ, Berenstein M, Dreja H, et al. A novel doxycycline inducible autoregulatory plasmid which displays on/off regulation suited to gene therapy applications. Gene Ther 2000 Dec; 7 (24): 2061-70
25. Graham LD. Ecdysone-controlled expression of transgenes. Expert Opin Biol Ther 2002 Jun; 2 (5): 525-35
26. Ngan ES, Schillinger K, DeMayo F, et al. The mifepristone-inducible gene regulatory system in mouse models of disease and gene therapy. Semin Cell Dev Biol. 2002 Apr; 13 (2): 143-9
27. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009 Aug; 10 (8): 578-85
28. Annoni A, Brown BD, Cantore A, et al. In vivo delivery of a microRNAregulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 2009 Dec; 114 (25): 5152-61
29. Sant SM, Suarez TM, Moalli MR, et al. Molecular lysis of synovial lining cells by in vivo herpes simplex virus-thymidine kinase gene transfer. Hum Gene Ther 1998 Dec; 9 (18): 2735-43
30. Deyle DR, Russell DW. Adeno-associated virus vector integration. Curr Opin Mol Ther 2009 Aug; 11 (4): 442-7
31. Mease P, WeiN, Fudman E, et al. Local treatment for inflammatory arthritis: a phase 1/2 clinical study of intra-articular administration of a recombinant adeno-associated vector containing a TNF-alpha antagonist gene [platform presentation 2084]. Annual Meeting of theACR/ARHP; 2007 Nov 10; Boston (MA), S793
32. Smolen JS, Redlich K, Zwerina J, et al. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol 2005 Jun; 28 (3): 239-48
33. van Vollenhoven RF. New and future agents in the treatment of rheumatoid arthritis. Discov Med 2010 Apr; 9 (47): 319-27
34. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acutephase reactants. Arthritis Rheum 2011 Jan; 63 (1): 43-52
35. Burmester GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011 May; 70 (5): 755-9
36. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebocontrolled, dose-ranging trial. Arthritis Rheum 2006May; 54 (5): 1390-400
37. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008 Nov; 67 (11): 1516-23
38. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximabs Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010 Sep; 69 (9): 1629-35
39. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 2010 Sep; 49 (9): 1683-93
40. Cohen SB, Emery P, GreenwaldMW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 Sep; 54 (9): 2793-806
41. Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009 Nov; 68 (11): 1708-14
42. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 Nov; 349 (20): 1907-15
43. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl JMed 2005 Sep; 353 (11): 1114-23
44. Buchschacher GL, Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood 2000 Apr; 95 (8): 2499-504
45. Gouze E, Pawliuk R, Gouze JN, et al. Lentiviral-mediated gene delivery to synovium: potnt intra-articular expression with amplification by inflammation. Mol Ther 2003 Apr; 7 (4): 460-6
46. Lin YL, Noël D, Mettling C, et al. Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis. Hum Gene Ther 2004 Jun; 15 (6): 588-96
47. Pauwels K, Gijsbers R, Toelen J, et al. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 2009 Dec; 9 (6): 459-74
48. Kremer EJ, Boutin S, Chillon M, et al. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J Virol 2000 Jan; 74 (1): 505-12
49. Seshidhar Reddy P, Ganesh S, Limbach MP, et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003 Jul 5; 311 (2): 384-93
50. Coura RoS, Nardi NB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J 2007; 4: 99
51. Mueller C, Flotte TR. Clinical gene therapy using recombinant adenoassociated virus vectors. Gene Ther 2008 Jun; 15 (11): 858-63
52. Wang J, Xie J, Lu H, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci U S A 2007 Aug; 104 (32): 13104-9
53. Arai Y, Kubo T, Fushiki S, et al. Gene delivery to human chondrocytes by an adeno associated virus vector. J Rheumatol 2000 Apr; 27 (4): 979-82
54. Goater J, Müller R, Kollias G, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol 2000 Apr; 27 (4): 983-9
55. Madry H, CucchiariniM, Terwilliger EF, et al. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Hum Gene Ther 2003 Mar; 14 (4): 393-402
56. Veron P, Allo V, Rivière C, et al. Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol 2007 May; 81 (10): 5385-94
57. Apparailly F, Bouquet C, Millet V, et al. Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis. Gene Ther 2002 Feb; 9 (3): 192-200
58. Chan JM, Villarreal G, Jin WW, et al. Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 2002 Dec; 6 (6): 727-36
59. Cottard V, Mulleman D, Bouille P, et al. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther 2000 Nov; 7 (22): 1930-9
60. Pan RY, Chen SL, Xiao X, et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000 Feb; 43 (2): 289-97
61. Watanabe S, Imagawa T, Boivin GP, et al. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Mol Ther 2000 Aug; 2 (2): 147-52
62. Zhang HG, Xie J, Yang P, et al. Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther 2000 Nov; 11 (17): 2431-42
63. Adriaansen J, Tas SW, Klarenbeek PL, et al. Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intraarticular gene therapy. Ann Rheum Dis 2005 Dec; 64 (12): 1677-84
64. Apparailly F, Khoury M, Vervoordeldonk MJ, et al. Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints.HumGene Ther 2005 Apr; 16 (4): 426-34
65. DiPrimio N, McPhee SW, Samulski RJ. Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. Curr Opin Mol Ther 2010 Oct; 12 (5): 553-60
66. Young SM, Samulski RJ. Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within theAAVterminal repeat. ProcNatlAcad SciUSA2001Nov; 98 (24): 13525-30
67. Khoury M, Adriaansen J, Vervoordeldonk MJ, et al. Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med 2007 Jul; 9 (7): 596-604
68. Adriaansen J, Khoury M, de Cortie CJ, et al. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis 2007 Sep; 66 (9): 1143-50
69. Brown BD, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007 Dec; 25 (12): 1457-67
70. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 2008 Jun; 15 (11): 840-8